Skip to content
TrialScanner

NCT05337553

A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy

Phase 3Active, not recruitingBHVNLead

Registry record

Lead sponsor
Biohaven Pharmaceuticals, Inc.
Conditions
Spinal Muscular Atrophy; Neuromuscular Diseases; SMA
Primary completion
Sep 25, 2024Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT05337553 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT05337553: A Study to Evaluate the... | TrialScanner